Response of dasatinib in different phase of chronic myeloid leukaemia patients

Moshammat Naznin Begum; M. A. Khan; Tasneem Ara; Akhil Ranjon Biswas; Mafruha Akter; M. Manirul Islam; Humayra Nazneen; Muhammad Nurul Farhad

doi:10.18203/2320-6012.ijrms20244091

Authors

Moshammat Naznin Begum Department of Haematology, Dhaka Medical College, Dhaka, Bangladesh
M. A. Khan Department of Haematology & BMT Unit, Dhaka Medical College, Dhaka, Bangladesh
Tasneem Ara Department of Haematology, Dhaka Medical College, Dhaka, Bangladesh
Akhil Ranjon Biswas Department of Haematology & BMT Unit, Dhaka Medical College, Dhaka, Bangladesh
Mafruha Akter Department of Haematology, Dhaka Medical College, Dhaka, Bangladesh
M. Manirul Islam Department of Haematology & BMT Unit, Dhaka Medical College, Dhaka, Bangladesh
Humayra Nazneen Department of Haematology & BMT Unit, Dhaka Medical College, Dhaka, Bangladesh
Muhammad Nurul Farhad Department of Haematology, Dhaka Medical College, Dhaka, Bangladesh

DOI:

https://doi.org/10.18203/2320-6012.ijrms20244091

Keywords:

Chronic myeloid leukemia, Dasatinib, Philadelphia chromosome, Imatinib resistance, Molecular response

Abstract

Background: Chronic myeloid leukemia (CML) is a stem cell disorder caused by a chromosomal abnormality that results in the formation of the Philadelphia chromosome. This abnormality leads to the production of the Bcr-Abl tyrosine kinase, which drives the uncontrolled proliferation of cells. Imatinib, a tyrosine kinase inhibitor (TKI), revolutionized the treatment of CML, but resistance and intolerance in some patients have necessitated alternative therapies such as Dasatinib, a potent multitargeted inhibitor of Bcr-Abl and Src-family kinases. This study was aims to assess the efficacy and safety of Dasatinib in CML patients who were either newly diagnosed or resistant/intolerant to Imatinib.

Methods: A prospective observational study was conducted at Dhaka Medical College & Hospital from July 2016 to June 2017. A total 31 patients with different phases of CML were included in this study. All patients were treated with Dasatinib 100 mg daily and monitored over 12 months. Molecular responses were assessed through quantitative PCR and hematologic responses were evaluated via complete blood counts.

Results: Among the 31 patients, two died and two discontinued treatment. Of the remaining 27, 23 (85%) achieved complete hematologic response (CHR), 12 (44%) achieved major molecular response (MMR) and 3 (11%) attained complete molecular response (CMR). All four chronic-phase CML (CML-CP) patients who received Dasatinib as frontline therapy achieved molecular response within one month of starting therapy. Responses were lower in more advanced disease stages, with two blast-phase patients dying.

Conclusions: Dasatinib demonstrated significant efficacy and safety in treating CML, particularly in chronic-phase patients and those resistant to Imatinib.

Metrics

Metrics Loading ...

References

Goldman JM, Mughal TI. Chronic myloid leukemia in: A. victor Hoff brand, Danial Catovsky, Edward GD. Tuddenham, Anther R, Green, editors, Postgraduate Hematology 6th edition, 2011: 483-502.

Luke R Shier, Tracy 1 George, Pathology of the myelo proliferative neoplasm in John P.G Daniet A. Bectilu, Alanf L, Robert TM, Frixos P, George M.R. editors. Wintrobe's Clinial hematology, 13th ed. Philadelphia. Lippincott Williams & Wilkins. 2014; 75.

Jemal A. Siegel R, Ku J. Alcassess statistics 2010 CA. Cancer J Clin. 2010;60:277-300.

Kantarjian H, Sawyers C, Hochhaus A. hematologic and cytogenetic responses to Imatinibmesylate in chronic myelogenous leukemia, N Engl J Med. 2002: 346:645-52.

Gratwohl A, Brand R, Apperley J. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Eurpoe 2006; transplant activity, long-term data and current results. An analysis by the C25hronic leukemia working party of the European group for blood and marrow transplantation (EBMT). Hematol. 2006:91:513-21.

Olivieri A, Manzione L. "Dasatinib: a new step in molecular target therapy". Annals of oncology official journal of the European Society for Medical Oncology/ESMO. 2007;18(6):42-6.

Han L, Schuringa J, Mulder A, Vellenga E. "Dasatinib impairs long- term expansion of leukemic progenitors in a subset of acute myeloid leukemia cases". Annals of hematol. 2010;89(9):861-71.

Shah NP, Nicoll JM, Nagar B.Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor Imatinib (ST1571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002; 2:117-25.

Donato NJ, Wu JY, Stapley J. BCR-ABL independence and LYN kinase overexpressin in chronic myelogenous leukemia cells selected for resistance to ST1571. Blood. 2003;101:690-8.

Soverini S, Colarossi S, Gnani A. Contribution of ABL kinase domain mutations to Imatinib resistance in different subsets of Philadelphia-positive patients. Clin Cancer Res. 2006;12:7374-9.

Kantarjian HM, Shah NP, Cortes JE. Dasatinib or Imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trail (DASISION). Blood. 2012;119(5):1123-9.

Alattar M, Kantarjian H, Jabbour E. Clinical significance of complete cytogenetic response (CCyR) and major molecular response (MMR) achieved with different treatment modalities used as frontline therapy in chronic myeloid leukemia (CML) chronic phase (CP) [abstrict], Blood. 2011;118:21.

Cortes JE, Jones D, O' Brien S. Results of Dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia, J ClinOncol. 2010;28(3):398- 404.

Cortes JE, Jones D, O' Brien S. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase, J Clin Oncol. 2010;28(3):392-7.

O'Hare T. Walters DK, Stoffregen EP. In vitro activity of Ber-Abl inhibitors AMN107 and BMS-354825 against clinically relevant Imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65:4500-5.

Van Etten RA, Shannon KM. Focus on myeloproliferative diseases and myelodysplastic syndromes. Cancer Cell. 2004;6:547-52.

Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood. 2008;112:4808-17.

Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007;7:441-53.

O'Hare T, Walters DK, Stoffregen EP. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant ImatinibresistantAbl kinase domain mutants. Cancer Res. 2005;65:4500-5.

Talpaz M, Shah N, Kantarjian H. Dasatinib in Imatinib-resistant Philadelphia-chromosome positive leukemias. N Engl J Med. 2006;354:2531-41.

Kantarjian H, Talpaz M, O'Brien S. Survival benefit with Imatinibmesylate therapy in patients with accelerated-phase chronic myelogenous leukemia- comparison with historic experience. Cancer. 2005;103:2099-108.

Druker BJ, Guilhot F, O'Brien SG. Five-year follow-up of patients receiving Imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17.

Apperley J, Cortes JE, Kim DW. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after Imatinib failure: the start a trial. J Clin Oncol. 2009;27:3472-9.

Hochhaus A, Kantarjian HM, Baccarani M. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of Imatinib therapy. Blood. 2007;109:2303-9.

Kantarjian H, Pasquini R, Hamerschlak N. Dasatinib or high-dose Imatinib for chronic-phase chronic myeloid leukemia after failure of first-line Imatinib: a randomized phase 2 trial. Blood. 2007;109:5143-50.

Natoli C, Perrucci B, Perrotti F, Falchi L, Iacobelli S, Consorzio Interuniversitario Nazionale per Bio-Oncologia (CINBO). Tyrosine kinase inhibitors. Curr Cancer Drug Targets. 2010;10:462-83.